Clinical Trial Update: Raltegravir Switch for Toxicity or Adverse Events [Phase 2]

View source ↗

Summary

Phase 2 trial update on switching HIV patients to raltegravir due to toxicity or adverse events while on antiretroviral therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Catholic University of the Sacred Heart | Conditions: HIV/AIDS, Antiretroviral Therapy | Phase 2 | Status: COMPLETED